Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -2.34%10 EV-to-OCF is -13.40 as of Jul. 15, 2026. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Kestra Medical Technologies ranks better than 84.21% on this metric.
The historical rank and industry rank for Kestra Medical Technologies's EV-to-OCF or its related term are showing as below:
KMTS'
s EV-to-OCF Range Over the Past 10 Years
Min: -18.16 Med: -12.46 Max: -6.81
Current: -13.4
During the past 4 years, the highest EV-to-OCF of Kestra Medical Technologies was -6.81. The lowest was -18.16. And the median was -12.46.
KMTS's EV-to-OCF is ranked better than 84.21% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 7.66
vs KMTS: -13.40
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kestra Medical Technologies (NAS:KMTS) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kestra Medical Technologies's PE Ratio (TTM) for today is calculated as:
Kestra Medical Technologies's share price for today is $24.24.
Kestra Medical Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kestra Medical Technologies EV-to-OCF Related Terms
Kestra Medical Technologies EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's EV-to-OCF falls into.
Kestra Medical Technologies's current Enterprise Value is $1,166.70 Mil.
Kestra Medical Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a EV-to-OCF of -13.40 as of Jul. 15, 2026. According to the industry distribution chart, Kestra Medical Technologies ranks #135 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 15.8%.
Is Kestra Medical Technologies' EV-to-OCF too high?
Kestra Medical Technologies' current EV-to-OCF is -13.40. Based on the distribution chart, Kestra Medical Technologies ranks #135 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' EV-to-OCF compare to ATRC and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #135 out of 855 companies for EV-to-OCF. This places Kestra Medical Technologies in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.66, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current EV-to-OCF is -13.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current EV-to-OCF of -13.40. The current EV-to-OCF is -13.40. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current EV-to-OCF is -13.40 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score
Get the complete analysis for KMTS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
